RESUMO
RATIONALE AND OBJECTIVES: The authors evaluate MS-325, a new albumin-targeted magnetic resonance imaging (MRI) contrast agent, for its pharmacokinetics, biodistribution, and elimination characteristics in multiple animal species. METHODS: Studies were performed in rats, rabbits, and nonhuman primates at intravenous doses ranging from 0.025 to 0.20 mmol/kg. Concentrations of MS-325 in blood, urine, feces, and organs were determined using gadolinium-153-labeled MS-325 and gamma counting or by using non-labeled MS-325 and inductively coupled plasma atomic emission spectrometry. RESULTS: In rabbits and nonhuman primates, MS-325 is approximately 85% to 95% bound to serum proteins and, as a result, exhibits low volume of distribution (Vd) values, 0.11 to 0.14 L/kg, and a long elimination half-life (Te1/2), 2 to 3 hours. Some dose-dependence in the parameters is apparent in rabbits. MS-325 is eliminated primarily through the renal system in non-human primates. In contrast, the behavior of MS-325 in rats is different, exhibiting increased biliary excretion, a larger Vd value, and a shorter Te1/2. CONCLUSIONS: The pharmacokinetics and elimination profile of MS-325, including vascular retention and renal excretion, are favorable for use in humans as an intravascular contrast agent for MRI.
Assuntos
Meios de Contraste/farmacocinética , Imageamento por Ressonância Magnética/métodos , Compostos Organometálicos/farmacocinética , Animais , Proteínas Sanguíneas/metabolismo , Meios de Contraste/metabolismo , Avaliação Pré-Clínica de Medicamentos , Feminino , Gadolínio/metabolismo , Gadolínio/farmacocinética , Imagem do Acúmulo Cardíaco de Comporta , Meia-Vida , Aumento da Imagem , Infusões Intravenosas , Macaca fascicularis , Masculino , Compostos Organometálicos/metabolismo , Papio , Ligação Proteica , Coelhos , Ratos , Ratos Sprague-Dawley , Distribuição TecidualAssuntos
Quelantes , Meios de Contraste/administração & dosagem , Gadolínio , Angiografia por Ressonância Magnética , Animais , Quelantes/farmacocinética , Quelantes/toxicidade , Meios de Contraste/farmacocinética , Meios de Contraste/toxicidade , Combinação de Medicamentos , Gadolínio/farmacocinética , Gadolínio/toxicidade , Gadolínio DTPA , Meia-Vida , Haplorrinos , Humanos , Injeções Intravenosas , Meglumina/farmacocinética , Meglumina/toxicidade , Taxa de Depuração Metabólica/fisiologia , Compostos Organometálicos/farmacocinética , Compostos Organometálicos/toxicidade , Ácido Pentético/análogos & derivados , Ácido Pentético/farmacocinética , Ácido Pentético/toxicidade , Ligação Proteica/fisiologia , Coelhos , Ratos , Albumina Sérica/metabolismo , Especificidade da EspécieRESUMO
PURPOSE: To evaluate the protein-binding and signal enhancement characteristics of MS-325, a gadolinium-based magnetic resonance (MR) imaging blood pool agent that binds to albumin, and compare results with those obtained with existing gadolinium- and iron oxide-based agents. MATERIALS AND METHODS: Protein binding in human plasma was measured by means of ultrafiltration. T1 relaxation times (20 MHz) were measured in human plasma or ex vivo samples from rabbits and monkeys injected with 0.1 mmol of MS-325 per kilogram of body weight. Imaging (three-dimensional fast imaging with steady-state precession, or FISP) was performed at 1.0 T in phantoms, which contained varying concentrations of different agents, or rabbits after injection of 0.015-0.100 mmol/kg MS-325. RESULTS: MS-325 is 80%-96% bound in human plasma and exhibits a relaxivity approximately six to 10 times that of gadolinium diethylenetriaminepentaacetic acid (DTPA). Images of phantoms containing MS-325 were significantly brighter than those containing existing gadolinium chelates or iron particles (monocrystalline iron oxide nanoparticle, or MION) at equivalent concentrations. Findings of in vivo studies indicated strong, persistent plasma T1 reduction with MS-325 for 1 hour (T1 of MS-325, 50-100 msec; T1 of Gd-DTPA, 200-400 msec) and strong vascular enhancement on MR images. CONCLUSION: MS-325 is highly protein bound after injection and provides vascular signal enhancement superior to that provided with other agents. As the first gadolinium-based blood pool agent in human trials, MS-325 has the potential to enhance both dynamic and steady-state MR angiograms.